Trial · NCT01415752
Participant flow40
How many started, completed or left each group, period by period.
1 to 20 of 40
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction (Step 1) | STARTED | Induction: Bendamustine + Rituximab Then Maintenance: Rituximab | 94 | |
| Induction (Step 1) | STARTED | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Rituximab | 93 | |
| Induction (Step 1) | STARTED | Induction: Bendamustine + Rituximab Then Maintenance: Lenalidomide + Rituximab | 93 | |
| Induction (Step 1) | STARTED | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Lenalidomide + Rituximab | 93 | |
| Induction (Step 1) | Included in the Analysis of Adverse Events | Induction: Bendamustine + Rituximab Then Maintenance: Rituximab | 93 | |
| Induction (Step 1) | Included in the Analysis of Adverse Events | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Rituximab | 92 | |
| Induction (Step 1) | Included in the Analysis of Adverse Events | Induction: Bendamustine + Rituximab Then Maintenance: Lenalidomide + Rituximab | 93 | |
| Induction (Step 1) | Included in the Analysis of Adverse Events | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Lenalidomide + Rituximab | 92 | |
| Induction (Step 1) | Included in the Efficacy Analysis | Induction: Bendamustine + Rituximab Then Maintenance: Rituximab | 90 | |
| Induction (Step 1) | Included in the Efficacy Analysis | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Rituximab | 90 | |
| Induction (Step 1) | Included in the Efficacy Analysis | Induction: Bendamustine + Rituximab Then Maintenance: Lenalidomide + Rituximab | 89 | |
| Induction (Step 1) | Included in the Efficacy Analysis | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Lenalidomide + Rituximab | 89 | |
| Induction (Step 1) | COMPLETED | Induction: Bendamustine + Rituximab Then Maintenance: Rituximab | 90 | |
| Induction (Step 1) | COMPLETED | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Rituximab | 90 | |
| Induction (Step 1) | COMPLETED | Induction: Bendamustine + Rituximab Then Maintenance: Lenalidomide + Rituximab | 89 | |
| Induction (Step 1) | COMPLETED | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Lenalidomide + Rituximab | 89 | |
| Induction (Step 1) | NOT COMPLETED | Induction: Bendamustine + Rituximab Then Maintenance: Rituximab | 4 | |
| Induction (Step 1) | NOT COMPLETED | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Rituximab | 3 | |
| Induction (Step 1) | NOT COMPLETED | Induction: Bendamustine + Rituximab Then Maintenance: Lenalidomide + Rituximab | 4 | |
| Induction (Step 1) | NOT COMPLETED | Induction: Bendamustine + Rituximab + Bortezomib Then Maintenance: Lenalidomide + Rituximab | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01415752/flow